Gentherm Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Gentherm Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $554.98M | Mar 15, 2013 |
| FY2012 | Dec 31, 2011 | $369.59M | Mar 15, 2013 |
| FY2012 | Dec 31, 2010 | $112.40M | Mar 15, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.50B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.46B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.47B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.20B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $1.05B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $913.10M | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | $230.38M | Feb 20, 2020 |
| FY2019 | Sep 30, 2019 | $240.06M | Feb 20, 2020 |
| FY2019 | Jun 30, 2019 | $243.33M | Feb 20, 2020 |
| FY2019 | Mar 31, 2019 | $257.92M | Feb 20, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $362.18M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $366.43M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $351.62M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $273.65M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $303.63M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $268.10M | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | $65.62M | Feb 20, 2020 |
| FY2019 | Sep 30, 2019 | $74.69M | Feb 20, 2020 |
| FY2019 | Jun 30, 2019 | $72.71M | Feb 20, 2020 |
| FY2019 | Mar 31, 2019 | $75.31M | Feb 20, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $95.39M | Feb 25, 2016 |
| FY2015 | Dec 31, 2014 | $70.12M | Feb 25, 2016 |
| FY2015 | Dec 31, 2013 | $33.82M | Feb 25, 2016 |
| FY2014 | Dec 31, 2012 | $17.87M | Mar 2, 2015 |
| FY2013 | Dec 31, 2011 | $9.66M | Mar 11, 2014 |
| FY2012 | Dec 31, 2010 | $9.45M | Mar 15, 2013 |
| FY2011 | Dec 31, 2009 | $723.0K | Mar 15, 2012 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $82.70M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $107.02M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $77.44M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $48.31M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $115.01M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $89.22M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $84.26M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $72.79M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $97.10M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $106.12M | Feb 26, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.76M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $88.70M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $94.36M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $85.72M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $75.21M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $68.04M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $72.48M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $79.90M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $82.48M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $72.92M | Feb 26, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $170.05M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $155.11M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $155.58M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $132.69M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $109.55M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $105.04M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $118.68M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $137.40M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $139.62M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $115.25M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.79M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $109.65M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $119.27M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $14.95M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $143.08M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $110.70M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $118.80M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $118.43M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $49.88M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $108.40M | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.67M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $73.31M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $37.60M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $39.70M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $38.47M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $17.22M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $23.73M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $41.54M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $50.79M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $66.32M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.40B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.25B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.23B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $1.24B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $935.34M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.02B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $738.83M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $803.05M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $883.41M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $843.03M | Feb 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $676.11M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $630.61M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $589.65M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $567.03M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $281.54M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $436.51M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $254.74M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $323.35M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $329.53M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $382.63M | Feb 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $720.32M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $616.95M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $644.72M | Feb 19, 2026 |
| FY2025 | Dec 31, 2022 | $672.27M | Feb 19, 2026 |
| FY2024 | Dec 31, 2021 | $653.81M | Feb 19, 2025 |
| FY2023 | Dec 31, 2020 | $586.33M | Feb 21, 2024 |
| FY2022 | Dec 31, 2019 | $484.10M | Feb 24, 2023 |
| FY2021 | Dec 31, 2018 | $479.70M | Feb 17, 2022 |
| FY2020 | Dec 31, 2017 | $553.87M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $460.41M | Feb 20, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $108.92M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $99.60M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $104.07M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $119.77M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $66.03M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $68.02M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $64.57M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $55.31M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $69.69M | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $51.74M | Feb 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $714.09M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $695.80M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $624.38M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $590.66M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $566.22M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $472.78M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $413.09M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $363.97M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $293.65M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $256.92M | Feb 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $160.83M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $134.13M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $149.67M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $153.89M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $190.61M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $268.35M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $50.44M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $39.62M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $103.17M | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $177.19M | Feb 26, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $189.07M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $220.20M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $222.84M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $235.10M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $38.75M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $192.43M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $80.62M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $139.89M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $144.67M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $171.53M | Feb 23, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 20, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 20, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 20, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 20, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 20, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 20, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 20, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 20, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 30.53M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 30.79M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 31.54M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 33.20M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 33.01M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 32.92M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | 32.67M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 33.86M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | 36.76M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 36.53M | Feb 23, 2018 |